4D MOLECULAR THERAPEUTICS IN (FDMT)
US35104E1001 - Common Stock
Taking everything into account, FDMT scores 4 out of 10 in our fundamental rating. FDMT was compared to 588 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for FDMT as it has an excellent financial health rating, but there are worries on the profitability. FDMT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year FDMT has reported negative net income.
In the past year FDMT has reported a negative cash flow from operations.
FDMT had negative earnings in each of the past 5 years.
In the past 5 years FDMT always reported negative operating cash flow.
1.2 Ratios
FDMT has a Return On Assets (-49.84%) which is comparable to the rest of the industry.
The Return On Equity of FDMT (-55.03%) is better than 64.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.84% | ||
| ROE | -55.03% | ||
| ROIC | N/A |
ROA(3y)-30.3%
ROA(5y)-39.06%
ROE(3y)-33.86%
ROE(5y)-57.61%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
FDMT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
FDMT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FDMT has more shares outstanding
FDMT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for FDMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
FDMT has an Altman-Z score of 20.77. This indicates that FDMT is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 20.77, FDMT belongs to the best of the industry, outperforming 93.17% of the companies in the same industry.
There is no outstanding debt for FDMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 20.77 |
ROIC/WACCN/A
WACC9.27%
2.3 Liquidity
FDMT has a Current Ratio of 15.65. This indicates that FDMT is financially healthy and has no problem in meeting its short term obligations.
FDMT has a Current ratio of 15.65. This is amongst the best in the industry. FDMT outperforms 91.30% of its industry peers.
FDMT has a Quick Ratio of 15.65. This indicates that FDMT is financially healthy and has no problem in meeting its short term obligations.
FDMT has a better Quick ratio (15.65) than 91.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 15.65 | ||
| Quick Ratio | 15.65 |
3. Growth
3.1 Past
FDMT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.48%, which is quite impressive.
FDMT shows a strong growth in Revenue. In the last year, the Revenue has grown by 1224.70%.
Measured over the past years, FDMT shows a small growth in Revenue. The Revenue has been growing by 7.96% on average per year.
EPS 1Y (TTM)20.48%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q10.71%
Revenue 1Y (TTM)1224.7%
Revenue growth 3Y15.04%
Revenue growth 5Y7.96%
Revenue growth Q2Q1557.84%
3.2 Future
The Earnings Per Share is expected to grow by 0.84% on average over the next years.
Based on estimates for the next years, FDMT will show a very strong growth in Revenue. The Revenue will grow by 62.55% on average per year.
EPS Next Y-18.81%
EPS Next 2Y-14.64%
EPS Next 3Y-20.95%
EPS Next 5Y0.84%
Revenue Next Year-74.55%
Revenue Next 2Y-42.58%
Revenue Next 3Y-55.49%
Revenue Next 5Y62.55%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
FDMT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year FDMT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as FDMT's earnings are expected to decrease with -20.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.64%
EPS Next 3Y-20.95%
5. Dividend
5.1 Amount
No dividends for FDMT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4D MOLECULAR THERAPEUTICS IN
NASDAQ:FDMT (4/30/2024, 3:30:02 PM)
After market: 23.93 0 (0%)23.93
-0.32 (-1.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.22B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.84% | ||
| ROE | -55.03% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 15.65 | ||
| Quick Ratio | 15.65 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)20.48%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-18.81%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)1224.7%
Revenue growth 3Y15.04%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y